Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation.

Pidala J, Kim J, Jim H, Kharfan-Dabaja MA, Nishihori T, Fernandez HF, Tomblyn M, Perez L, Perkins J, Xu M, Janssen WE, Veerapathran A, Betts BC, Locke FL, Ayala E, Field T, Ochoa L, Alsina M, Anasetti C.

Haematologica. 2012 Dec;97(12):1882-9. doi: 10.3324/haematol.2012.067140.

2.

Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease.

Pidala J, Kim J, Alsina M, Ayala E, Betts BC, Fernandez HF, Field T, Jim H, Kharfan-Dabaja MA, Locke FL, Mishra A, Nishihori T, Ochoa-Bayona L, Perez L, Riches M, Anasetti C.

Haematologica. 2015 Jul;100(7):970-7. doi: 10.3324/haematol.2015.123588.

3.

The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate.

Perez-Simón JA, Martino R, Parody R, Cabrero M, Lopez-Corral L, Valcarcel D, Martinez C, Solano C, Vazquez L, Márquez-Malaver FJ, Sierra J, Caballero D.

Haematologica. 2013 Apr;98(4):526-32. doi: 10.3324/haematol.2012.065599.

4.

Quality of life associated with sirolimus for prevention of graft-versus-host disease: results from a randomized trial.

Jim HS, Barata A, Small BJ, Jacobsen PB, Pidala J.

Haematologica. 2014 Mar;99(3):548-53. doi: 10.3324/haematol.2013.088781.

5.

Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.

Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, Fay JW, Nademanee A, Antin JH, Christiansen NP, van der Jagt R, Herzig RH, Litzow MR, Wolff SN, Longo WL, Petersen FB, Karanes C, Avalos B, Storb R, Buell DN, Maher RM, Fitzsimmons WE, Wingard JR.

Blood. 1998 Oct 1;92(7):2303-14.

6.

Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis.

Snyder DS, Palmer J, Gaal K, Stein AS, Pullarkat V, Sahebi F, Vora N, Nakamura R, Forman SJ.

Biol Blood Marrow Transplant. 2010 Feb;16(2):281-6. doi: 10.1016/j.bbmt.2009.09.020.

7.

Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.

Rosenbeck LL, Kiel PJ, Kalsekar I, Vargo C, Baute J, Sullivan CK, Wood L, Abdelqader S, Schwartz J, Srivastava S, Abonour R, Robertson MJ, Nelson RP Jr, Cornetta K, Fausel CA, Farag SS.

Biol Blood Marrow Transplant. 2011 Jun;17(6):916-22. doi: 10.1016/j.bbmt.2010.09.017.

8.

Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant.

Ceberio I, Devlin SM, Sauter C, Barker JN, Castro-Malaspina H, Giralt S, Ponce DM, Lechner L, Maloy MA, Goldberg JD, Perales MA.

Leuk Lymphoma. 2015 Mar;56(3):663-70. doi: 10.3109/10428194.2014.930851.

9.

Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.

Cutler C, Kim HT, Hochberg E, Ho V, Alyea E, Lee SJ, Fisher DC, Miklos D, Levin J, Sonis S, Soiffer RJ, Antin JH.

Biol Blood Marrow Transplant. 2004 May;10(5):328-36.

10.
11.

Tacrolimus with mini-methotrexate as prophylaxis for graft-versus-host disease in pediatric patients after allogeneic peripheral blood stem cell transplant or bone marrow transplant.

Sabapathy C, Gourde JA, Khan SP, Rodriguez V.

J Pediatr Hematol Oncol. 2008 Dec;30(12):945-9. doi: 10.1097/MPH.0b013e318180bc31.

PMID:
19131788
12.

Towards rational graft-versus-host disease prophylaxis.

Bucher CM, Passweg JR.

Haematologica. 2012 Dec;97(12):1779-80. doi: 10.3324/haematol.2012.080226. No abstract available.

13.
14.

Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation.

Kharfan-Dabaja M, Mhaskar R, Reljic T, Pidala J, Perkins JB, Djulbegovic B, Kumar A.

Cochrane Database Syst Rev. 2014 Jul 25;(7):CD010280. doi: 10.1002/14651858.CD010280.pub2. Review.

PMID:
25061777
15.

Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.

Alyea EP, Li S, Kim HT, Cutler C, Ho V, Soiffer RJ, Antin JH.

Biol Blood Marrow Transplant. 2008 Aug;14(8):920-6. doi: 10.1016/j.bbmt.2008.05.024.

16.

Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens.

Cutler C, Li S, Kim HT, Laglenne P, Szeto KC, Hoffmeister L, Harrison MJ, Ho V, Alyea E, Lee SJ, Soiffer R, Sonis S, Antin JH.

Biol Blood Marrow Transplant. 2005 May;11(5):383-8.

17.

Anti-thymocyte globulin (thymoglobulin), tacrolimus, and sirolimus as acute graft-versus-host disease prophylaxis for unrelated hematopoietic stem cell transplantation.

Al-Kadhimi Z, Gul Z, Rodriguez R, Chen W, Smith D, Mitchell A, Abidi M, Ayash L, Deol A, Lum L, Forman S, Ratanatharathorn V, Uberti J.

Biol Blood Marrow Transplant. 2012 Nov;18(11):1734-44. doi: 10.1016/j.bbmt.2012.06.004.

18.

Feasibility of tacrolimus, methotrexate, and prednisolone as a graft-versus-host disease prophylaxis in non-T-cell-depleted haploidentical hematopoietic stem cell transplantation for children.

Mochizuki K, Kikuta A, Ito M, Sano H, Akaihata M, Kobayashi S, Ohto H, Hosoya M.

Clin Transplant. 2011 Nov-Dec;25(6):892-7. doi: 10.1111/j.1399-0012.2010.01352.x.

PMID:
21070366
19.
20.

Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.

Solomon SR, Sizemore CA, Sanacore M, Zhang X, Brown S, Holland HK, Morris LE, Bashey A.

Biol Blood Marrow Transplant. 2015 Jul;21(7):1299-307. doi: 10.1016/j.bbmt.2015.03.003.

Supplemental Content

Support Center